Compile Data Set for Download or QSAR
Report error Found 253 Enz. Inhib. hit(s) with all data for entry = 10284
TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525065(US11168102, Example 9.)
Affinity DataKd:  0.366nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525146(US11168102, Example 32-31.)
Affinity DataIC50: 3.53nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525147(US11168102, Example 32-32.)
Affinity DataIC50: 4.77nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525070(US11168102, Example 18.)
Affinity DataIC50: 5.79nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524861(US11168102, Example 1.)
Affinity DataKd:  6.20nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524925(US11168102, Example 1-15.)
Affinity DataKd:  6.29nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525148(US11168102, Example 32-51.)
Affinity DataIC50: 6.77nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525128(US11168102, Example 32-19.)
Affinity DataKd:  6.92nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525044(US11168102, Example 2.)
Affinity DataKd:  7.36nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525132(US11168102, Example 57.)
Affinity DataIC50: 7.65nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525055(US11168102, Example 8-4.)
Affinity DataIC50: 7.66nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524864(US11168102, Example 1-3.)
Affinity DataKd:  7.86nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525067(US11168102, Example 12.)
Affinity DataKd:  7.94nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525049(US11168102, Example 4.)
Affinity DataKd:  7.97nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525128(US11168102, Example 32-19.)
Affinity DataIC50: 8.82nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524861(US11168102, Example 1.)
Affinity DataIC50: 9nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525132(US11168102, Example 57.)
Affinity DataKd:  9.19nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525049(US11168102, Example 4.)
Affinity DataIC50: 10.8nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525065(US11168102, Example 9.)
Affinity DataIC50: 11.9nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525071(US11168102, Example 19.)
Affinity DataIC50: 12.3nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525056(US11168102, Example 8-5.)
Affinity DataIC50: 12.8nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524950(US11168102, Example 1-18.)
Affinity DataIC50: 12.8nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525044(US11168102, Example 2.)
Affinity DataIC50: 12.9nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524948(US11168102, Example 1-17.)
Affinity DataIC50: 13nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524863(US11168102, Example 1-2.)
Affinity DataKd:  13.4nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525142(US11168102, Example 24.)
Affinity DataIC50: 13.5nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525067(US11168102, Example 12.)
Affinity DataIC50: 13.6nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524910(US11168102, Example 1-13.)
Affinity DataKd:  13.8nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525120(US11168102, Example 28-6.)
Affinity DataIC50: 14nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525124(US11168102, Example 29-5.)
Affinity DataIC50: 14.8nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525126(US11168102, Example 31-1.)
Affinity DataIC50: 15nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525054(US11168102, Example 8-3.)
Affinity DataIC50: 15nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525035(US11168102, Example 1-22.)
Affinity DataKd:  15.1nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525088(US11168102, Example 25.)
Affinity DataIC50: 15.9nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525123(US11168102, Example 29-4.)
Affinity DataIC50: 15.9nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525070(US11168102, Example 18.)
Affinity DataKd:  16nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524880(US11168102, Example 1-5.)
Affinity DataKd:  16.3nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525126(US11168102, Example 31-1.)
Affinity DataKd:  16.4nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525050(US11168102, Example 6.)
Affinity DataKd:  17.3nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525072(US11168102, Example 21.)
Affinity DataIC50: 18nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524881(US11168102, Example 1-6.)
Affinity DataKd:  18.2nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524915(US11168102, Example 1-14.)
Affinity DataKd:  19nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525145(US11168102, Example 32-24.)
Affinity DataIC50: 19.1nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524910(US11168102, Example 1-13.)
Affinity DataIC50: 19.3nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525088(US11168102, Example 25.)
Affinity DataKd:  19.4nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525086(US11168102, Example 23.)
Affinity DataKd:  19.8nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524884(US11168102, Example 1-8.)
Affinity DataKd:  20nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM525042(US11168102, Example 1-30.)
Affinity DataKd:  20.1nMAssay Description:The purpose of this assay was to characterize the inhibitory activity of compounds on SOS1 nucleotide exchange of KRAS. Data was reported as IC50 val...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524884(US11168102, Example 1-8.)
Affinity DataIC50: 20.1nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Revolution Medicines

US Patent
LigandPNGBDBM524933(US11168102, Example 1-16.)
Affinity DataIC50: 20.4nMAssay Description:Using a GE Biacore 8K SPR instrument, avi-tagged SOS1 catalytic domain protein was immobilized to a level of approximately 6000 response units (RU) o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

Displayed 1 to 50 (of 253 total ) | Next | Last >>
Jump to: